Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China

BACKGROUND: Serum phosphorus control is critical for chronic kidney disease (CKD) 5D patients. Currently, clinical profile for an oral phosphorus binder in the mainland Chinese population is not available. OBJECTIVE: To establish the efficacy, safety, and tolerability of lanthanum carbonate in CKD 5...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jing, Zhang, Yi-Xiang, Yu, Xue-Qing, Liu, Zhi-Hong, Wang, Li-Ning, Chen, Jiang-Hua, Fan, Ya-Ping, Ni, Zhao-Hui, Wang, Mei, Yuan, Fa-Huan, Ding, Guo-Hua, Chen, Xiang-Mei, Zhang, Ai-Ping, Mei, Chang-Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570485/
https://www.ncbi.nlm.nih.gov/pubmed/23379590
http://dx.doi.org/10.1186/1471-2369-14-29

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570485/
https://www.ncbi.nlm.nih.gov/pubmed/23379590
http://dx.doi.org/10.1186/1471-2369-14-29

Ejemplares similares